E-LIB Suche - Ergebnisse für: Vanover, Kim E.

1

Pharmacological characterization of AC-262536, a novel sele..:

Piu, Fabrice ; Gardell, Luis R. ; Son, Thomas...
The Journal of Steroid Biochemistry and Molecular Biology. 109 (2008) 1-2 - p. 129-137 , 2008

Link: https://doi.org/10.1016/..

2

Identification of novel selective V2 receptor non-peptide a..:

Del Tredici, Andria L. ; Vanover, Kim E. ; Knapp, Anne E....
Biochemical Pharmacology. 76 (2008) 9 - p. 1134-1141 , 2008

Link: https://doi.org/10.1016/..

3

P2‐032: ITI‐007 (LUMATEPERONE) FOR THE TREATMENT OF AGITATI..:

Satlin, Andrew ; Vanover, Kim ; Glass, Steven...
Alzheimer's & Dementia. 14 (2018) 7S_Part_12 - p. , 2018

Link: https://doi.org/10.1016/..

4

High-throughput screens identify a lipid nanoparticle that ..:

Huayamares, Sebastian G. ; Lokugamage, Melissa P. ; Rab, Regina...
Journal of Controlled Release. 357 (2023) - p. 394-403 , 2023

Link: https://doi.org/10.1016/..

5

Optimization of lipid nanoparticles for the delivery of neb..:

Lokugamage, Melissa P. ; Vanover, Daryll ; Beyersdorf, Jared...
Nature Biomedical Engineering. 5 (2021) 9 - p. 1059-1068 , 2021

Link: https://doi.org/10.1038/..

6

Pharmacologic profile of ITI-333: a novel molecule for trea..:

Snyder, Gretchen L. ; Li, Peng ; Martin, Terry...
Psychopharmacology. 241 (2024) 7 - p. 1477-1490 , 2024

Link: https://doi.org/10.1007/..

7

Adjunctive lumateperone (ITI‐007) in the treatment of bipol..:

Suppes, Trisha ; Durgam, Suresh ; Kozauer, Susan G....
Bipolar Disorders. 25 (2023) 6 - p. 478-488 , 2023

Link: https://doi.org/10.1111/..

8

Single doses of a highly selective inhibitor of phosphodies..:

Khalsa, Sahib S. ; Victor, Teresa A. ; Kuplicki, Rayus...
Neuropsychopharmacology. 47 (2022) 10 - p. 1844-1853 , 2022

Link: https://doi.org/10.1038/..

9

Safety and tolerability of lumateperone for the treatment o..:

Kane, John M ; Durgam, Suresh ; Satlin, Andrew...
International Clinical Psychopharmacology. 36 (2021) 5 - p. 244-250 , 2021

Link: https://doi.org/10.1097/..

10

Safety and tolerability of lumateperone 42 mg: An open-labe..:

Correll, Christoph U. ; Vanover, Kimberly E. ; Davis, Robert E....
Schizophrenia Research. 228 (2021) - p. 198-205 , 2021

Link: https://doi.org/10.1016/..

11

P.468 Cardiometabolic safety of lumateperone (ITI-007): pos..:

Satlin, A. ; Durgam, S. ; Vanover, K.E....
European Neuropsychopharmacology. 40 (2020) - p. S265-S266 , 2020

Link: https://doi.org/10.1016/..

12

185 The Safety and Tolerability of Lumateperone 42 mg for t..:

Kane, John M ; Vanover, Kimberly E ; Durgam, Suresh...
CNS Spectrums. 25 (2020) 2 - p. 316-317 , 2020

Link: https://doi.org/10.1017/..

13

T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALU..:

Kane, John M ; Mates, Sharon ; Vanover, Kimberly E...
Schizophrenia Bulletin. 46 (2020) Supplement_1 - p. S310-S310 , 2020

Link: https://doi.org/10.1093/..

14

186 Results From a 12-Month Open-label Safety Study of Luma..:

Correll, Christoph U. ; Vanover, Kimberly E ; Durgam, Suresh...
CNS Spectrums. 25 (2020) 2 - p. 317-318 , 2020

Link: https://doi.org/10.1017/..

15

P.446 Efficacy and safety of lumateperone (ITI-007) in the ..:

Durgam, S. ; Satlin, A. ; Vanover, K.E....
European Neuropsychopharmacology. 40 (2020) - p. S253-S254 , 2020

Link: https://doi.org/10.1016/..